Kawata N, Takimoto Y, Hirano D, Yamamoto T, Hirakata H, Yamanaka Y, Okada Y, Chino K, Sugimoto S, Igarashi T
Department of Urology, Nihon University School of Medicine Surugadai Hospital, Japan.
Hinyokika Kiyo. 1996 Jan;42(1):1-4.
We studied the relationship between clinical stage and tumor infiltrating lymphocytes (TIL) in 26 cases of renal cell carcinoma. In 10 patients, interferon-gamma (IFN-gamma) was administered preoperatively (administration group); 5 patients had low stage (Robson < or = I), and the remaining 5 patients had high stage (Robson > or = II) tumors. The other 16 patients underwent nephrectomy alone without preoperative IFN administration (control group); 11 patients had low stage, and the remaining 5 patients had high stage tumors. Immunohistochemical studies of tumor infiltrating lymphocytes in renal cell carcinoma showed a significantly high incidence of CD3, CD8, CD11b and ICAM-1 in the administration group, while CD4, LFA-1 and Ber-MAC3 were increased without significance (p < 0.05). Concerning clinical stage (Robson), a significant increase in CD3, CD8, CD11b and ICAM-1 was observed in the patients with high-stage tumors in the administration group compared to those in the control group (p < 0.05). This suggested that TIL could be changed by preoperative administration of IFN-gamma.
我们研究了26例肾细胞癌患者的临床分期与肿瘤浸润淋巴细胞（TIL）之间的关系。10例患者术前给予γ-干扰素（IFN-γ）（给药组）；5例患者为低分期（Robson≤I期），其余5例患者为高分期（Robson≥II期）肿瘤。另外16例患者未术前给予IFN，仅接受肾切除术（对照组）；11例患者为低分期，其余5例患者为高分期肿瘤。肾细胞癌肿瘤浸润淋巴细胞的免疫组化研究显示，给药组中CD3、CD8、CD11b和ICAM-1的发生率显著升高，而CD4、LFA-1和Ber-MAC3虽有升高但无统计学意义（p<0.05）。关于临床分期（Robson分期），与对照组相比，给药组高分期肿瘤患者的CD3、CD8、CD11b和ICAM-1显著增加（p<0.05）。这表明术前给予IFN-γ可改变TIL。
